Back to Search
Start Over
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
- Source :
- Circulation: Cardiovascular Quality & Outcomes; Jul2011, Vol. 4 Issue 4, p448-458, 11p
- Publication Year :
- 2011
-
Abstract
- The article focuses on the effect of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors when used in non-ST-segment elevation acute coronary syndromes (NSTE ACS). The authors analyzed 12 randomized clinical trials that they assessed for tirofiban, eptifibatide and lamifiban. They found that an 11% reduction in 30-day death/myocardial infarction when upstream GP IIb/IIa inhibitor was used. The authors claim significant but modest ischemic benefit brought by the use of the inhibitor.
Details
- Language :
- English
- ISSN :
- 19417713
- Volume :
- 4
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- Circulation: Cardiovascular Quality & Outcomes
- Publication Type :
- Academic Journal
- Accession number :
- 67201610
- Full Text :
- https://doi.org/10.1161/CIRCOUTCOMES.110.960294